Targeting the Metabolic-Immune Regulator SLC35F6 Enhances Temozolomide and Anti-PD-L1 Therapy in Glioma.
A dual-ligand nanoplatform designed to facilitate trans-BBB delivery of siSLC35F6, TMZ, and an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody (α-PD-L1) monoclonal antibody is developed.